Home / News / CMS advises EPIRUS Biopharmaceuticals, Inc. on the...

CMS advises EPIRUS Biopharmaceuticals, Inc. on the acquisition of Bioceros Holding B.V.

24/09/2015

CMS has advised EPIRUS Biopharmaceuticals, Inc. on the acquisition of Bioceros Holding B.V. EPIRUS Biopharmaceuticals, Inc. is a NASDAQ listed biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). This acquisition enables EPIRUS to expand its biosimilar pipeline.

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines.

The CMS team that assisted EPIRUS comprised Reinout Slot, Clair Wermers, Tjeerd Hoekstra, Katja van Kranenburg-Hanspians, Paulus van den Bos, Niels Koene, Rogier de Vrey, Ellen Gielen, Dena Mokhberolsafa, Kirsten van Vliet and Erik Vorst.

Related people

Picture of Reinout Slot
Reinout Slot
Partner
Amsterdam
Picture of Clair Wermers
Clair Wermers
Counsel
Amsterdam
Picture of Tjeerd Hoekstra
Tjeerd Hoekstra
Advocaat
Amsterdam
Katja-vanKranenburg-CMS-NL
Katja van Kranenburg - Hanspians
Partner
Amsterdam
Picture of Paulus van den Bosch
Paulus van den Bos
Advocaat
Amsterdam
Niels-Koene-CMS-NL
Niels Koene
Advocaat
Amsterdam
Picture of Rogier de Vrey
Rogier de Vrey
Partner
Amsterdam
Picture of Ellen Gielen
Ellen Gielen
Partner
Utrecht
Picture of Dena Mokhberolsafa
Dena Mokhberolsafa
Advocaat
Amsterdam
Picture of Erik Vorst
Erik Vorst
Partner
Amsterdam
Picture of Kirsten van Vliet
Kirsten van Vliet
Show more Show less